94 related articles for article (PubMed ID: 27236772)
1. Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma.
Rini BI; Tomita Y; Melichar B; Ueda T; Grünwald V; Fishman MN; Uemura H; Oya M; Bair AH; Andrews GI; Rosbrook B; Jonasch E
Clin Genitourin Cancer; 2016 Dec; 14(6):499-503. PubMed ID: 27236772
[TBL] [Abstract][Full Text] [Related]
2. Overall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II study.
Oya M; Tomita Y; Fukasawa S; Shinohara N; Habuchi T; Rini BI; Fujii Y; Kamei Y; Umeyama Y; Bair AH; Uemura H
Cancer Sci; 2017 Jun; 108(6):1231-1239. PubMed ID: 28267243
[TBL] [Abstract][Full Text] [Related]
3. Axitinib for the management of metastatic renal cell carcinoma.
Escudier B; Gore M
Drugs R D; 2011; 11(2):113-26. PubMed ID: 21679004
[TBL] [Abstract][Full Text] [Related]
4. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial.
Gross-Goupil M; Kwon TG; Eto M; Ye D; Miyake H; Seo SI; Byun SS; Lee JL; Master V; Jin J; DeBenedetto R; Linke R; Casey M; Rosbrook B; Lechuga M; Valota O; Grande E; Quinn DI
Ann Oncol; 2018 Dec; 29(12):2371-2378. PubMed ID: 30346481
[TBL] [Abstract][Full Text] [Related]
5. Concise drug review: pazopanib and axitinib.
van Geel RM; Beijnen JH; Schellens JH
Oncologist; 2012; 17(8):1081-9. PubMed ID: 22733795
[TBL] [Abstract][Full Text] [Related]
6. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.
Cohen EE; Tortorici M; Kim S; Ingrosso A; Pithavala YK; Bycott P
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1261-70. PubMed ID: 25315258
[TBL] [Abstract][Full Text] [Related]
7. Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion.
Du Four S; Maenhout SK; Benteyn D; De Keersmaecker B; Duerinck J; Thielemans K; Neyns B; Aerts JL
Cancer Immunol Immunother; 2016 Jun; 65(6):727-40. PubMed ID: 27098427
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of axitinib for metastatic renal cell carcinoma: Real-world data on patients with renal impairment.
Minami K; Osawa T; Kojima T; Hara T; Eto M; Takeuchi A; Nakai Y; Ueda K; Ozawa M; Uemura M; Ohba K; Tamura K; Shindo T; Nakagomi H; Takahashi A; Anai S; Yokomizo A; Morizane S; Kimura T; Shimazui T; Miyauchi Y; Mitsuzuka K; Hara H; Yoshimura K; Shiina H; Ito YM; Murai S; Nishiyama H; Shinohara N; Kitamura H;
Urol Oncol; 2023 Nov; 41(11):458.e9-458.e19. PubMed ID: 37798145
[TBL] [Abstract][Full Text] [Related]
9. Influence of genetic polymorphisms in vascular endothelial-related genes on the clinical outcome of axitinib in patients with metastatic renal cell carcinoma.
Numakura K; Igarashi R; Takahashi M; Nara T; Kanda S; Saito M; Narita S; Inoue T; Niioka T; Miura M; Habuchi T
Cancer Biol Ther; 2024 Dec; 25(1):2312602. PubMed ID: 38327067
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of plasminogen activator inhibitor-1 in biomarker exploration using multiplex immunoassay in patients with metastatic renal cell carcinoma treated with axitinib.
Honma N; Inoue T; Tsuchiya N; Koizumi A; Yamamoto R; Nara T; Kanda S; Huang M; Numakura K; Saito M; Narita S; Satoh S; Habuchi T
Health Sci Rep; 2020 Dec; 3(4):e197. PubMed ID: 33088925
[TBL] [Abstract][Full Text] [Related]
11. Axitinib Induced Recurrent Pneumothorax following Near-Complete Response of Renal Cell Carcinoma Lung Metastasis: An Unexpected Complication.
Socola F; Loaiza-Bonilla A; Benedetto P
Case Rep Oncol Med; 2012; 2012():390702. PubMed ID: 23326741
[TBL] [Abstract][Full Text] [Related]
12. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
13. Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial.
Hutson TE; Al-Shukri S; Stus VP; Lipatov ON; Shparyk Y; Bair AH; Rosbrook B; Andrews GI; Vogelzang NJ
Clin Genitourin Cancer; 2017 Feb; 15(1):72-76. PubMed ID: 27498023
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.
George S; Motzer RJ; Hammers HJ; Redman BG; Kuzel TM; Tykodi SS; Plimack ER; Jiang J; Waxman IM; Rini BI
JAMA Oncol; 2016 Sep; 2(9):1179-86. PubMed ID: 27243803
[TBL] [Abstract][Full Text] [Related]
15. Key predictive factors for efficacy of axitinib in first-line metastatic renal cell carcinoma: subgroup analysis in Japanese patients from a randomized, double-blind phase II study.
Tomita Y; Fukasawa S; Oya M; Uemura H; Shinohara N; Habuchi T; Rini BI; Chen Y; Bair AH; Ozono S; Naito S; Akaza H
Jpn J Clin Oncol; 2016 Nov; 46(11):1031-1041. PubMed ID: 27572087
[TBL] [Abstract][Full Text] [Related]
16. Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Wells JC; Stukalin I; Norton C; Srinivas S; Lee JL; Donskov F; Bjarnason GA; Yamamoto H; Beuselinck B; Rini BI; Knox JJ; Agarwal N; Ernst DS; Pal SK; Wood LA; Bamias A; Alva AS; Kanesvaran R; Choueiri TK; Heng DY
Eur Urol; 2017 Feb; 71(2):204-209. PubMed ID: 27318422
[TBL] [Abstract][Full Text] [Related]
17. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.
Cella D; Grünwald V; Nathan P; Doan J; Dastani H; Taylor F; Bennett B; DeRosa M; Berry S; Broglio K; Berghorn E; Motzer RJ
Lancet Oncol; 2016 Jul; 17(7):994-1003. PubMed ID: 27283863
[TBL] [Abstract][Full Text] [Related]
18. Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features.
Kim JH; Park I; Lee JL
Cancer Chemother Pharmacol; 2016 Aug; 78(2):325-32. PubMed ID: 27324136
[TBL] [Abstract][Full Text] [Related]
19. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ;
Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544
[TBL] [Abstract][Full Text] [Related]
20. The Role of Nephrectomy for Kidney Cancer in the Era of Targeted and Immune Therapies.
Vaishampayan UN
Am Soc Clin Oncol Educ Book; 2016; 35():e16-20. PubMed ID: 27249719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]